Logo image of TRHC

TABULA RASA HEALTHCARE INC (TRHC) Stock Fundamental Analysis

NASDAQ:TRHC - Nasdaq - US8733791011 - Common Stock - Currency: USD

10.5  +0.09 (+0.86%)

Fundamental Rating

2

TRHC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. TRHC has a bad profitability rating. Also its financial health evaluation is rather negative. TRHC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRHC has reported negative net income.
In the past year TRHC has reported a negative cash flow from operations.
TRHC had negative earnings in each of the past 5 years.
TRHC had a positive operating cash flow in 4 of the past 5 years.
TRHC Yearly Net Income VS EBIT VS OCF VS FCFTRHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -26.82%, TRHC perfoms like the industry average, outperforming 46.51% of the companies in the same industry.
Industry RankSector Rank
ROA -26.82%
ROE N/A
ROIC N/A
ROA(3y)-23.32%
ROA(5y)-18.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRHC Yearly ROA, ROE, ROICTRHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 400

1.3 Margins

Looking at the Gross Margin, with a value of 23.61%, TRHC is doing worse than 83.72% of the companies in the same industry.
In the last couple of years the Gross Margin of TRHC has declined.
The Profit Margin and Operating Margin are not available for TRHC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.61%
TRHC Yearly Profit, Operating, Gross MarginsTRHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 -40

More info and screens

1

2. Health

2.1 Basic Checks

TRHC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TRHC has been increased compared to 1 year ago.
Compared to 1 year ago, TRHC has a worse debt to assets ratio.
TRHC Yearly Shares OutstandingTRHC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
TRHC Yearly Total Debt VS Total AssetsTRHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.66, we must say that TRHC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TRHC (-0.66) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.66
ROIC/WACCN/A
WACC8.36%
TRHC Yearly LT Debt VS Equity VS FCFTRHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.57 indicates that TRHC should not have too much problems paying its short term obligations.
TRHC's Current ratio of 1.57 is on the low side compared to the rest of the industry. TRHC is outperformed by 60.47% of its industry peers.
TRHC has a Quick Ratio of 1.47. This is a normal value and indicates that TRHC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.47, TRHC is not doing good in the industry: 60.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.47
TRHC Yearly Current Assets VS Current LiabilitesTRHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.00% over the past year.
TRHC shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.28%.
The Revenue has been growing by 17.54% on average over the past years. This is quite good.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112%
Revenue 1Y (TTM)22.28%
Revenue growth 3Y1.71%
Revenue growth 5Y17.54%
Sales Q2Q%24.02%

3.2 Future

TRHC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.23% yearly.
Based on estimates for the next years, TRHC will show a quite strong growth in Revenue. The Revenue will grow by 17.28% on average per year.
EPS Next Y94.12%
EPS Next 2Y52.76%
EPS Next 3Y34.23%
EPS Next 5YN/A
Revenue Next Year21.88%
Revenue Next 2Y18.38%
Revenue Next 3Y17.28%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
TRHC Yearly Revenue VS EstimatesTRHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
TRHC Yearly EPS VS EstimatesTRHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRHC. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 40.37 indicates a quite expensive valuation of TRHC.
TRHC's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TRHC is cheaper than 74.42% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.08. TRHC is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 40.37
TRHC Price Earnings VS Forward Price EarningsTRHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRHC Per share dataTRHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TRHC's earnings are expected to grow with 34.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.76%
EPS Next 3Y34.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRHC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TABULA RASA HEALTHCARE INC

NASDAQ:TRHC (11/2/2023, 8:12:48 PM)

10.5

+0.09 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-07 2023-11-07/amc
Earnings (Next)03-04 2024-03-04/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners47.24%
Ins Owner Change0%
Market Cap284.02M
Analysts48.89
Price Target10.71 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.51%
Min EPS beat(2)85.99%
Max EPS beat(2)125.03%
EPS beat(4)3
Avg EPS beat(4)27.01%
Min EPS beat(4)-127.59%
Max EPS beat(4)125.03%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.19%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)3.05%
Revenue beat(4)3
Avg Revenue beat(4)1.2%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)3.05%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)77.78%
EPS NY rev (1m)0%
EPS NY rev (3m)85.48%
Revenue NQ rev (1m)0.41%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 40.37
P/S 0.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)0.26
Fwd EY2.48%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS12.5
BVpS-2.89
TBVpS-9.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.61%
FCFM N/A
ROA(3y)-23.32%
ROA(5y)-18.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.61%
F-Score2
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.37%
Cap/Sales 5.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.47
Altman-Z -0.66
F-Score2
WACC8.36%
ROIC/WACCN/A
Cap/Depr(3y)72.04%
Cap/Depr(5y)69.33%
Cap/Sales(3y)10.17%
Cap/Sales(5y)8.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112%
EPS Next Y94.12%
EPS Next 2Y52.76%
EPS Next 3Y34.23%
EPS Next 5YN/A
Revenue 1Y (TTM)22.28%
Revenue growth 3Y1.71%
Revenue growth 5Y17.54%
Sales Q2Q%24.02%
Revenue Next Year21.88%
Revenue Next 2Y18.38%
Revenue Next 3Y17.28%
Revenue Next 5YN/A
EBIT growth 1Y-16.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year137.28%
EBIT Next 3Y39.09%
EBIT Next 5YN/A
FCF growth 1Y0.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-320.17%
OCF growth 3YN/A
OCF growth 5Y-16.67%